Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Merck & Company (MRK)

Merck & Company (MRK)
93.30 x 80 94.80 x 1
Post-market by (Cboe BZX)
93.11 -1.62 (-1.71%) 03/21/25 [NYSE]
93.30 x 80 94.80 x 1
Post-market 93.50 +0.39 (+0.42%) 19:42 ET
Quote Overview for Fri, Mar 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
93.07
Day High
94.68
Open 94.58
Previous Close 94.73 94.73
Volume 68,435,700 68,435,700
Avg Vol 17,613,959 17,613,959
Stochastic %K 50.27% 50.27%
Weighted Alpha -26.48 -26.48
5-Day Change -1.46 (-1.54%) -1.46 (-1.54%)
52-Week Range 81.04 - 134.63 81.04 - 134.63
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 235,199,200
  • Shares Outstanding, K 2,526,036
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 20,221 M
  • EBITDA $ 24,720 M
  • 60-Month Beta 0.35
  • Price/Sales 3.73
  • Price/Cash Flow 10.01
  • Price/Book 5.17

Options Overview Details

View History
  • Implied Volatility 27.18% ( +1.02%)
  • Historical Volatility 20.60%
  • IV Percentile 84%
  • IV Rank 69.34%
  • IV High 32.52% on 01/29/25
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.52
  • Today's Volume 34,316
  • Volume Avg (30-Day) 45,189
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 620,109
  • Open Int (30-Day) 689,443

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.16
  • Number of Estimates 7
  • High Estimate 2.25
  • Low Estimate 2.10
  • Prior Year 2.07
  • Growth Rate Est. (year over year) +4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.86 +4.78%
on 02/26/25
Period Open: 89.50
97.37 -4.38%
on 03/07/25
+3.61 (+4.03%)
since 02/21/25
3-Month
81.04 +14.89%
on 02/18/25
Period Open: 98.05
102.97 -9.58%
on 01/07/25
-4.94 (-5.04%)
since 12/20/24
52-Week
81.04 +14.89%
on 02/18/25
Period Open: 123.62
134.63 -30.84%
on 06/25/24
-30.51 (-24.68%)
since 03/21/24

Most Recent Stories

More News
2 Beaten-Down Stocks to Buy on the Dip

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics...

CRSP : 41.22 (+0.12%)
MRK : 93.11 (-1.71%)
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease...

JNJ : 163.63 (+0.37%)
MRK : 93.11 (-1.71%)
LLY : 837.57 (-0.59%)
ABBV : 210.01 (-0.92%)
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market valueThe numerous challenges plaguing the company resulted in the dilution of the stock’s market...

MRK : 93.11 (-1.71%)
SMMT : 19.75 (+1.59%)
MRNA : 32.66 (+0.65%)
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy

/CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada approved KEYTRUDA® (pembrolizumab),...

MRK : 93.11 (-1.71%)
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25.Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales performance...

MRK : 93.11 (-1.71%)
MRNA : 32.66 (+0.65%)
GSK : 39.24 (-0.43%)
PFE : 26.28 (+0.34%)
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?

Gilead Sciences, Inc. GILD hit a 52-week high of $119.96 on March 10. The stock is currently trading at $111.44.Shares have also gained 5.5% in the past month compared with the industry’s growth of 1.2%....

MRK : 93.11 (-1.71%)
GILD : 107.08 (+1.14%)
GSK : 39.24 (-0.43%)
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

The Dow Jones Industrial Average (DJINDICES: ^DJI) is one of the most-watched stock indexes on Wall Street. Its list of components is rather small; that small list, however, means these are cherry-picked...

TMUS : 255.84 (-0.46%)
CVX : 164.75 (-0.01%)
VZ : 43.99 (+0.55%)
T : 27.02 (+0.86%)
$SPX : 5,667.56 (+0.08%)
MRK : 93.11 (-1.71%)
$DOWI : 41,985.35 (+0.08%)
Zacks Investment Ideas feature highlights: Molson Coors, Merck & Co. and Deutsche Telekom

For Immediate ReleaseChicago, IL – March 11, 2025– Today, Zacks Investment Ideas feature highlights Molson Coors TAP, Merck & Co. MRK and Deutsche Telekom DTEGY.Safe-Haven Stocks: 3 Top Picks for Navigating...

DTEGY : 36.3800 (+0.75%)
TAP : 58.89 (-0.17%)
MRK : 93.11 (-1.71%)
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

MRK : 93.11 (-1.71%)
MRNA : 32.66 (+0.65%)
Safe Haven Stocks: 3 Top Picks for Navigating Volatility

After two years of steady gains, the stock market is now experiencing one of its sharpest corrections in recent history. US stock indexes have entered correction territory, with technology and semiconductor...

DTEGY : 36.3800 (+0.75%)
TAP : 58.89 (-0.17%)
MRK : 93.11 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 95.78
2nd Resistance Point 95.23
1st Resistance Point 94.17
Last Price 93.11
1st Support Level 92.56
2nd Support Level 92.01
3rd Support Level 90.95

See More

52-Week High 134.63
Fibonacci 61.8% 114.16
Fibonacci 50% 107.84
Fibonacci 38.2% 101.51
Last Price 93.11
52-Week Low 81.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals